AJP - Lung Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Lung Cell Mol Physiol 280: L771-L778, 2001;
1040-0605/01 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schwartz, D. A.
Right arrow Articles by Wohlford-Lenane, C. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schwartz, D. A.
Right arrow Articles by Wohlford-Lenane, C. L.
Vol. 280, Issue 4, L771-L778, April 2001

Inhibition of LPS-induced airway hyperresponsiveness and airway inflammation by LPS antagonists

David A. Schwartz1, William J. Christ2, Steven R. Kleeberger3, and Christine L. Wohlford-Lenane1

1 Pulmonary, Critical Care, and Occupational Medicine Division, Department of Internal Medicine, Department of Veterans Affairs Medical Center and The University of Iowa, Iowa City, Iowa 52242; 2 Eisai Research Institute, Andover, Massachusetts 01810; and 3 Department of Environmental Health Sciences, The Johns Hopkins School of Hygiene and Public Health, Baltimore, Maryland 21205

To determine whether the inflammatory effects of inhaled endotoxin could be prevented, we pretreated mice with synthetic competitive antagonists (975, 1044, and 1287) for lipopolysaccharide (LPS) before a LPS inhalation challenge. In preliminary studies, we found that these LPS antagonists did not act as agonists in vitro (THP-1 cells) or in vivo (after intratracheal instillation of 10 µg) and that these compounds (at least 1 µg/ml) effectively antagonized the release of tumor necrosis factor-alpha by LPS-stimulated THP-1 cells. Pretreatment of mice with 10 µg of either 1044 or 1287 resulted in a decrease in the LPS-induced airway hyperreactivity. Moreover, pretreatment of mice with 10 µg of 975, 1044, or 1287 resulted in significant reductions in LPS-induced lung lavage fluid concentrations of total cells, neutrophils, and specific proinflammatory cytokines compared with mice pretreated with sterile saline. Using residual oil fly ash to induce airway inflammation, we found that the action of the LPS antagonists was specific to LPS-induced airway disease. These results suggest that LPS antagonists may be an effective and potentially safe treatment for endotoxin-induced airway disease.

asthma; endotoxin; lung inflammation; lipopolysaccharide


This article has been cited by other articles:


Home page
 Lab AnimHome page
J Hamacher, M Arras, F Bootz, M Weiss, R Schramm, and U Moehrlen
Microscopic wire guide-based orotracheal mouse intubation: description, evaluation and comparison with transillumination
Lab Anim, April 1, 2008; 42(2): 222 - 230.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
J. D. Savov, S. H. Gavett, D. M. Brass, D. L. Costa, and D. A. Schwartz
Neutrophils play a critical role in development of LPS-induced airway disease
Am J Physiol Lung Cell Mol Physiol, November 1, 2002; 283(5): L952 - L962.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online